We have previously described that transforming growth factor beta (TGB-β), a potent immunosuppressor, promotes Myosin II-driven contractility in melanoma.10 Interestingly, ROCKi reduced TGB-β levels in immunotherapy-resistant cells in vitro, which could lead to dampening of immunosuppression in vivo. The gene discussed is ROCK1; the disease is melanoma.